Vantage Financial Partners LLC Makes New $217,000 Investment in Merck & Co., Inc. (NYSE:MRK)

Vantage Financial Partners LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,643 shares of the company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in Merck & Co., Inc. by 3.8% during the fourth quarter. Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock worth $9,331,676,000 after buying an additional 3,153,333 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after purchasing an additional 4,731,152 shares in the last quarter. Norges Bank acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $3,108,366,000. Royal Bank of Canada lifted its position in shares of Merck & Co., Inc. by 12.8% during the fourth quarter. Royal Bank of Canada now owns 14,972,074 shares of the company’s stock worth $1,632,255,000 after purchasing an additional 1,696,151 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of Merck & Co., Inc. by 1.7% during the fourth quarter. Fisher Asset Management LLC now owns 13,566,968 shares of the company’s stock worth $1,479,071,000 after purchasing an additional 228,578 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.5 %

MRK opened at $125.76 on Tuesday. The firm’s fifty day moving average is $129.05 and its two-hundred day moving average is $125.26. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The firm has a market cap of $318.53 billion, a PE ratio of 139.73, a price-to-earnings-growth ratio of 2.44 and a beta of 0.38. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.13. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the business posted $1.40 earnings per share. Equities research analysts anticipate that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, July 8th. Stockholders of record on Monday, June 17th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 2.45%. The ex-dividend date was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is 342.22%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MRK shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. Berenberg Bank upped their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Truist Financial upped their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Societe Generale lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective on the stock. in a report on Monday, March 11th. Finally, Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

View Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.